Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Τίτλος | Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Psyrri, A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Batistatou A., Bournakis E., Timotheadou E., Gogas H., Aravantinos G., Christodoulou C., Makatsoris T., Linardou H., Pectasides D., Pavlidis N., Economopoulos T., & Fountzilas G. |
Journal | Ann Oncol |
Volume | 23 |
Issue | 6 |
Pagination | 1422-7 |
Date Published | 2012 Jun |
ISSN | 1569-8041 |
Λέξεις κλειδιά | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Disease-Free Survival, Female, Fluorouracil, Humans, Kaplan-Meier Estimate, Methotrexate, Middle Aged, Multivariate Analysis, Neoplasm Staging, Paclitaxel, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, RNA, Messenger, Transcription, Genetic, Tumor Burden, Ubiquitin-Conjugating Enzymes, Young Adult |
Abstract | BACKGROUND: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the prognostic and/or predictive significance of UBE2C messenger RNA (mRNA) expression on disease-free survival (DFS) and overall survival (OS) in high-risk operable breast cancer patients.METHODS: Five hundred and ninety-five high-risk breast cancer patients were treated in a two-arm trial evaluating postoperative, dose-dense sequential chemotherapy with epirubicin followed by CMF (cyclophosphamide, methotrexate and 5-fluorouracil) with or without paclitaxel (Taxol). RNA was extracted from 313 formalin-fixed primary tumor tissue samples followed by one-step quantitative RT-PCR for assessment of mRNA expression of UBE2C.RESULTS: High UBE2C mRNA expression was associated with poor DFS (Wald's P = 0.003) and OS (Wald's P = 0.005). High tumor grade, as well as high Ki67 protein expression, was more frequent in the high-expression group of UBE2C. Results of the Cox multivariate regression analysis revealed that high UBE2C mRNA expression remained an independent adverse prognostic factor for relapse (P = 0.037) and death (P = 0.05).CONCLUSIONS: High UBE2C mRNA expression was found to be of adverse prognostic significance in high-risk breast cancer patients. These findings need to be validated in larger cohorts. |
DOI | 10.1093/annonc/mdr527 |
Alternate Journal | Ann. Oncol. |
PubMed ID | 22056852 |